PDF(Pubmed)
Abstract：
UNASSIGNED: Baloxavir Marboxil is a per oral small-molecule antiviral for the treatment of influenza. While the efficacy and safety of Baloxavir Marboxil have been thoroughly characterized across an extensive clinical trial, studies on the effectiveness of Baloxavir Marboxil in a real-world setting are still scarce.
UNASSIGNED: We conducted an ambispective, observational, multi-center study that enrolled uncomplicated in-fluenza outpatients treated with Baloxavir Marboxil or Oseltamivir in East China. The primary endpoint was time from treatment to alleviation of all influenza symptoms (TTAIS). The secondary endpoints included time from treatment to alleviation of fever (TTAF) and household transmission during the duration of influenza.
UNASSIGNED: A total of 509 patients were enrolled. The median TTAIS in the Baloxavir Marboxil group and the Oseltamivir group was 28.0 h (IQR, 20.0 to 50.0) and 48.0 h (IQR, 30.0 to 67.0), respectively. The median TTAF in the Baloxavir Marboxil group and the Oseltamivir group was 18 h (IQR, 10.0-24.0) and 30.0 h (IQR, 19.0-48.0). In the COX multivariable analysis, Baloxavir Marboxil reduced the duration of influenza symptoms (HR = 1.36 [95%CI:1.12-1.64], p = 0.002) and the duration of fever (HR = 1.93 [95%CI:1.48-2.52], p < 0.001) compared to Oseltamivir. When antiviral drugs were given within 12-48 h after symptom onset, the Baloxavir Marboxil group had a significantly shorter TTAIS compared to the Oseltamivir group. There was no significant difference in the rate of adverse events between the two group (p = 0.555).
UNASSIGNED: Baloxavir Marboxil was superior to Oseltamivir in alleviating influenza symptoms in outpatients with uncomplicated influenza. Our findings suggested that compared to Oseltamivir, Baloxavir Marboxil might be more appropriate for patients with influenza 12- 48 h after symptom onset.
UNASSIGNED: We conducted an ambispective, observational, multi-center study that enrolled uncomplicated in-fluenza outpatients treated with Baloxavir Marboxil or Oseltamivir in East China. The primary endpoint was time from treatment to alleviation of all influenza symptoms (TTAIS). The secondary endpoints included time from treatment to alleviation of fever (TTAF) and household transmission during the duration of influenza.
UNASSIGNED: A total of 509 patients were enrolled. The median TTAIS in the Baloxavir Marboxil group and the Oseltamivir group was 28.0 h (IQR, 20.0 to 50.0) and 48.0 h (IQR, 30.0 to 67.0), respectively. The median TTAF in the Baloxavir Marboxil group and the Oseltamivir group was 18 h (IQR, 10.0-24.0) and 30.0 h (IQR, 19.0-48.0). In the COX multivariable analysis, Baloxavir Marboxil reduced the duration of influenza symptoms (HR = 1.36 [95%CI:1.12-1.64], p = 0.002) and the duration of fever (HR = 1.93 [95%CI:1.48-2.52], p < 0.001) compared to Oseltamivir. When antiviral drugs were given within 12-48 h after symptom onset, the Baloxavir Marboxil group had a significantly shorter TTAIS compared to the Oseltamivir group. There was no significant difference in the rate of adverse events between the two group (p = 0.555).
UNASSIGNED: Baloxavir Marboxil was superior to Oseltamivir in alleviating influenza symptoms in outpatients with uncomplicated influenza. Our findings suggested that compared to Oseltamivir, Baloxavir Marboxil might be more appropriate for patients with influenza 12- 48 h after symptom onset.
摘要：
■BaloxavirMarboxil是一种口服小分子抗病毒药物，用于治疗流感。虽然BaloxavirMarboxil的疗效和安全性已经在广泛的临床试验中得到了彻底的表征，关于BaloxavirMarboxil在现实世界中的有效性的研究仍然很少。
■我们进行了一次全面调查，观察,多中心研究纳入华东地区接受巴洛沙韦或奥司他韦治疗的无并发症流感门诊患者。主要终点是从治疗到缓解所有流感症状的时间（TTAIS）。次要终点包括在流感持续期间从治疗到缓解发热(TTAF)和家庭传播的时间。
■共纳入509例患者。BaloxavirMarboxil组和奥司他韦组的TTAIS中位数为28.0h（IQR，20.0至50.0)和48.0小时(IQR，30.0到67.0），分别。BaloxavirMarboxil组和奥司他韦组的TTAF中位数为18h（IQR，10.0-24.0)和30.0h(IQR，19.0-48.0）。在COX多变量分析中，BaloxavirMarboxil减少了流感症状的持续时间（HR=1.36[95CI：1.12-1.64]，p=0.002）和发热持续时间（HR=1.93[95CI：1.48-2.52]，p<0.001)与奥司他韦相比。当在症状发作后12-48小时内给予抗病毒药物时，与奥司他韦组相比,巴洛沙韦组的TTAIS显著缩短.两组之间的不良事件发生率没有显着差异（p=0.555）。
■在缓解无并发症流感门诊患者的流感症状方面，巴洛沙韦优于奥司他韦。我们的研究结果表明，与奥司他韦相比，BaloxavirMarboxil可能更适合症状发作后12-48h的流感患者。
■我们进行了一次全面调查，观察,多中心研究纳入华东地区接受巴洛沙韦或奥司他韦治疗的无并发症流感门诊患者。主要终点是从治疗到缓解所有流感症状的时间（TTAIS）。次要终点包括在流感持续期间从治疗到缓解发热(TTAF)和家庭传播的时间。
■共纳入509例患者。BaloxavirMarboxil组和奥司他韦组的TTAIS中位数为28.0h（IQR，20.0至50.0)和48.0小时(IQR，30.0到67.0），分别。BaloxavirMarboxil组和奥司他韦组的TTAF中位数为18h（IQR，10.0-24.0)和30.0h(IQR，19.0-48.0）。在COX多变量分析中，BaloxavirMarboxil减少了流感症状的持续时间（HR=1.36[95CI：1.12-1.64]，p=0.002）和发热持续时间（HR=1.93[95CI：1.48-2.52]，p<0.001)与奥司他韦相比。当在症状发作后12-48小时内给予抗病毒药物时，与奥司他韦组相比,巴洛沙韦组的TTAIS显著缩短.两组之间的不良事件发生率没有显着差异（p=0.555）。
■在缓解无并发症流感门诊患者的流感症状方面，巴洛沙韦优于奥司他韦。我们的研究结果表明，与奥司他韦相比，BaloxavirMarboxil可能更适合症状发作后12-48h的流感患者。
